APOE and neuroenergetics: An emerging paradigm in Alzheimer's disease

Neurobiology of Aging

Volumn 34, Issue 4, 2013, Pages 1007-1017

  Wolf, Andrew B ^a,b   Caselli, Richard J ^b,c   Reiman, Eric M ^b,d,e,f   Valla, Jon ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^c MAYO CLINIC   (United States)

^d BANNER ALZHEIMER S INSTITUTE   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; APOE; Apolipoprotein E; Biomarkers; Brain imaging; Cytochrome oxidase; Energy metabolism; FDG PET; FMRI; Mitochondria; Neurodegeneration; Neuroenergetics

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CARRIER PROTEIN; CYTOCHROME C OXIDASE; CYTOCHROME C1; FLUORODEOXYGLUCOSE F 18; TOMM40 PROTEIN; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUINOL CYTOCHROME C REDUCTASE CORE PROTEIN 2; UBIQUINOL CYTOCHROME C REDUCTASE SUBUNIT 4 ISOFORM 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ASTROCYTE; BRAIN NERVE CELL; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CEREBRAL METABOLIC RATE FOR GLUCOSE; CHROMOSOME 19; CYTOSKELETON; DIFFUSION TENSOR IMAGING; ENDOPHENOTYPE; ENERGY METABOLISM; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE DOSAGE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HOMOZYGOSITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TEMPORAL CORTEX; WHITE MATTER;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; ENERGY METABOLISM; HUMANS; MODELS, NEUROLOGICAL;

EID: 84872359922     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.10.011     Document Type: Review

References (157)

1. Aggerbeck L.P., Wetterau J.R., Weisgraber K.H., Wu C.C., Lindgren F.T. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J. Biol.Chem. 1988, 263:6249-6258.
2. Alexopoulos P., Richter-Schmidinger T., Horn M., Maus S., Reichel M., Sidiropoulos C., Rhein C., Lewczuk P., Doerfler A., Kornhuber J. Hippocampal volume differences between healthy young apolipoprotein E ε2 and ε4 carriers. J. Alzheimer's Dis. 2011, 26:207-210.
3. Allaman I., Bélanger M., Magistretti P.J. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011, 34:76-87.
4. Allaman I., Gavillet M., Bélanger M., Laroche T., Viertl D., Lashuel H.A., Magistretti P.J. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J. Neurosci. 2010, 30:3326-3338.
5. Andrews-Zwilling Y., Bien-Ly N., Xu Q., Li G., Bernardo A., Yoon S.Y., Zwilling D., Yan T.X., Chen L., Huang Y. Apolipoprotein E4 causes age- and tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010, 30:13707-13717.
6. Aoki K., Uchihara T., Sanjo N., Nakamura A., Ikeda K., Tsuchiya K., Wakayama Y. Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 2003, 34:875-880.
7. Ashford J.W., Mortimer J.A. Non-familial Alzheimer's disease is mainly due to genetic factors. J. Alzheimer's Dis. 2002, 4:169-177.
8. Bales K.R., Du Y., Holtzman D., Cordell B., Paul S.M. Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol. Aging 2000, 21:427-432.
9. Barros L.F., Porras O.H., Bittner C.X. Why glucose transport in the brain matters for PET. Trends Neurosci. 2005, 28:117-119.
10. Bekris L.M., Galloway N.M., Montine T.J., Schellenberg G.D., Yu C.-E. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153:409-417.
11. Bell R.D., Winkler E.A., Singh I., Sagare A.P., Deane R., Wu Z., Holtzman D.M., Betsholtz C., Armulik A., Sallstrom J., Berk B.C., Zlokovic B.V. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485:512-516.
12. Bellosta S., Nathan B.P., Orth M., Dong L.M., Mahley R.W., Pitas R.E. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 1995, 270:27063-27071.
13. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.-M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 2011, 14:750-756.
14. Bertram L., Tanzi R.E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci. 2008, 9:768-778.
15. Bolender N., Sickmann A., Wagner R., Meisinger C., Pfanner N. Multiple pathways for sorting mitochondrial precursor proteins. EMBO Rep. 2008, 9:42-49.
16. Boschert U., Merlo-Pich E., Higgins G., Roses A.D., Catsicas S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol. Dis. 1999, 6:508-514.
17. Boyle P.A., Wilson R.S., Aggarwal N.T., Tang Y., Bennett D.A. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006, 67:441-445.
18. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 1985, 76:1501-1513.
19. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.-Q., Xu Q., Fish J.D., Wyss-Coray T., Buttini M., Mucke L., Mahley R.W., Huang Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 2004, 24:2527-2534.
20. Brodbeck J., McGuire J., Liu Z., Meyer-Franke A., Balestra M.E., Jeong D.-E., Pleiss M., McComas C., Hess F., Witter D., Peterson S., Childers M., Goulet M., Liverton N., Hargreaves R., Freedman S., Weisgraber K.H., Mahley R.W., Huang Y. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 2011, 286:17217-17226.
21. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
22. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 2008, 1124:1-38.
23. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25:7709-7717.
24. Chang S., Ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W., Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18694-18699.
25. Chen H.-K., Ji Z.-S., Dodson S.E., Miranda R.D., Rosenblum C.I., Reynolds I.J., Freedman S.B., Weisgraber K.H., Huang Y., Mahley R.W. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer's disease. J. Biol. Chem. 2011, 286:5215-5221.
26. Chen H.-K., Liu Z., Meyer-Franke A., Brodbeck J., Miranda R.D., McGuire J.G., Pleiss M.A., Ji Z.S., Balestra M.E., Walker D.W., Xu Q., Jeong D.E., Budamagunta M.S., Voss J.C., Freedman S.B., Weisgraber K.H., Huang Y., Mahley R.W. Small-molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J. Biol. Chem. 2012, 287:5253-5266.
27. Chételat G., Desgranges B., Landeau B., Mézenge F., Poline J.B., de la Sayette V., Viader F., Eustache F., Baron J.-C. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008, 131:60-71.
28. Chételat G., Villain N., Desgranges B., Eustache F., Baron J.-C. Posterior cingulate hypometabolism in early Alzheimer's disease: what is the contribution of local atrophy versus disconnection?. Brain 2009, 132:e133.
29. Chroni A., Pyrpassopoulos S., Thanassoulas A., Nounesis G., Zannis V.I., Stratikos E. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry 2008, 47:9071-9080.
30. Chu S.H., Roeder K., Ferrell R.E., Devlin B., Demichele-Sweet M.A.A., Kamboh M.I., Lopez O.L., Sweet R.A. TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease. Neurobiol. Aging 2011, 32:2328.e1-2328.e9.
31. Cirrito J.R., Kang J.-E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008, 58:42-51.
32. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
33. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., DeKosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J. Neurosci. 2009, 29:14770-14778.
34. Conejero-Goldberg C., Hyde T.M., Chen S., Dreses-Werringloer U., Herman M.M., Kleinman J.E., Davies P., Goldberg T.E. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Mol. Psychiatry. 2011, 16:836-847.
35. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
36. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
37. Cruchaga C., Nowotny P., Kauwe J.S.K., Ridge P.G., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M., Alzheimer's Disease Neuroimaging Initiative Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch. Neurol. 2011, 68:1013-1019.
38. Dennis N.A., Browndyke J.N., Stokes J., Need A., Burke J.R., Welsh-Bohmer K.A., Cabeza R. Temporal lobe functional activity and connectivity in young adult APOE4 carriers. Alzheimers Dement. 2010, 6:303-311.
39. Detmer S.A., Chan D.C. Functions and dysfunctions of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 2007, 8:870-879.
40. Dong L.M., Weisgraber K.H. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 1996, 271:19053-19057.
41. Dong L.M., Wilson C., Wardell M.R., Simmons T., Mahley R.W., Weisgraber K.H., Agard D.A. Human apolipoprotein E. role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 1994, 269:22358-22365.
42. Drzezga A., Grimmer T., Riemenschneider M., Lautenschlager N., Siebner H., Alexopoulus P., Minoshima S., Schwaiger M., Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 2005, 46:1625-1632.
43. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., Schwaiger M., Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1104-1113.
44. Dumanis S.B., Tesoriero J.A., Babus L.W., Nguyen M.T., Trotter J.H., Ladu M.J., Weeber E.J., Turner R.S., Xu B., Rebeck G.W., Hoe H.S. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J. Neurosci. 2009, 29:15317-15322.
45. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 1998, 143:777-794.
46. Elshourbagy N.A., Liao W.S., Mahley R.W., Taylor J.M. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:203-207.
47. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M., Alzheimer's Disease International Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
48. Filbey F.M., Slack K.J., Sunderland T.P., Cohen R.M. Functional magnetic resonance imaging and magnetoencephalography differences associated with APOE e4 in young healthy adults. Neuroreport 2006, 17:1585-1590.
49. Filippini N., MacIntosh B.J., Hough M.G., Goodwin G.M., Frisoni G.B., Smith S.M., Matthews P.M., Beckmann C.F., Mackay C.E. Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7209-7214.
50. Friedland R.P., Brun A., Budinger T.F. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 1985, 1:228.
51. Geldmacher D.S., Fritsch T., McClendon M.J., Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol. 2011, 68:45-50.
52. Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., Craft S., Landreth G., Linnamägi U., Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 2010, 30:131-146.
53. Gomez-Isla T., West H.L., Rebeck G.W., Harr S.D., Growdon J.H., Locascio J.J., Perls T.T., Lipsitz L.A., Hyman B.T. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer's disease. Ann. Neurol. 1996, 39:62-70.
54. Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., Fish J.D., Masliah E., Hopkins P.C., Scearce-Levie K., Weisgraber K.H., Mucke L., Mahley R.W., Huang Y. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10966-10971.
55. Harris F.M., Brecht W.J., Xu Q., Mahley R.W., Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J. Biol. Chem. 2004, 279:44795-44801.
56. Harris F.M., Tesseur I., Brecht W.J., Xu Q., Mullendorff K., Chang S., Wyss-Coray T., Mahley R.W., Huang Y. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J. Biol. Chem. 2004, 279:3862-3868.
57. Hartman R.E., Wozniak D.F., Nardi A., Olney J.W., Sartorius L., Holtzman D.M. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp. Neurol. 2001, 170:326-344.
58. Hatters D.M., Peters-Libeu C.A., Weisgraber K.H. Apolipoprotein E structure: insights into function. Trends Biochem. Sci. 2006, 31:445-454.
59. Hatters D.M., Zhong N., Rutenber E., Weisgraber K.H. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J. Mol. Biol. 2006, 361:932-944.
60. Hedskog L., Brohede J., Wiehager B., Pinho C.M., Revathikumar P., Lilius L., Glaser E., Graff C., Karlström H., Ankarcrona M. Biochemical studies of poly-T variants in the Alzheimer's disease associated TOMM40 gene. J. Alzheimers Dis. 2012, 31:527-536.
61. Heise V., Filippini N., Ebmeier K.P., Mackay C.E. The APOE ε4 allele modulates brain white matter integrity in healthy adults. Mol. Psychiatry. 2011, 16:908-916.
62. Henderson S.T., Vogel J.L., Barr L.J., Garvin F., Jones J.J., Costantini L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. 2009, 6:31.
63. Herz J., Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 2006, 7:850-859.
64. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A. Mitochondrial abnormalities in Alzheimer' s disease. J. Neurosci. 2001, 21:3017-3023.
65. Hock M.B., Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annu. Rev. Physiol. 2009, 71:177-203.
66. Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006312.
67. Holtzman D.M., Pitas R.E., Kilbridge J., Nathan B., Mahley R.W., Bu G., Schwartz A.L. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9480-9484.
68. Hong M.-G., Alexeyenko A., Lambert J.-C., Amouyel P., Prince J.A. Genomewide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease. J. Hum. Genet. 2010, 55:707-709.
69. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 2010, 16:287-294.
70. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8838-8843.
71. Ibáñez V., Pietrini P., Alexander G.E., Furey M.L., Teichberg D., Rajapakse J.C., Rapoport S.I., Schapiro M.B., Horwitz B. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998, 50:1585-1593.
72. James R., Searcy J.L., Le Bihan T., Martin S.F., Gliddon C.M., Povey J., Deighton R.F., Kerr L.E., McCulloch J., Horsburgh K. Proteomic analysis of mitochondria in APOE transgenic mice and in response to an ischemic challenge. J. Cereb. Blood. Flow. Metab. 2011, 32:164-176.
73. Ji Y., Gong Y., Gan W., Beach T., Holtzman D.M., Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. Neuroscience 2003, 122:305-315.
74. Johnson S.C., La Rue A., Hermann B.P., Xu G., Koscik R.L., Jonaitis E.M., Bendlin B.B., Hogan K.J., Roses A.D., Saunders A.M., Lutz M.W., Asthana S., Green R.C., Sager M.A. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOEε3/ε3 genotype. Alzheimer's Dement. 2011, 7:456-465.
75. Jolivet R., Magistretti P.J., Weber B. Deciphering neuron-glia compartmentalization in cortical energy metabolism. Front. Neuroenergetics 2009, 1:4.
76. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
77. Klein R.C., Mace B.E., Moore S.D., Sullivan P.M. Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. Neuroscience 2010, 171:1265-1272.
78. Korwek K.M., Trotter J.H., Ladu M.J., Sullivan P.M., Weeber E.J. ApoE isoform-dependent changes in hippocampal synaptic function. Mol. Neurodegener. 2009, 4:21.
79. Li G., Bien-Ly N., Andrews-Zwilling Y., Xu Q., Bernardo A., Ring K., Halabisky B., Deng C., Mahley R.W., Huang Y. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 2009, 5:634-645.
80. Li Z., Okamoto K.-I., Hayashi Y., Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119:873-887.
81. Liang W.S., Chen K., Lee W., Sidhar K., Corneveaux J.J., Allen A.N., Myers A., Villa S., Meechoovet B., Pruzin J., Bandy D., Fleisher A.S., Langbaum J.B., Huentelman M.J., Jensen K., Dunckley T., Caselli R.J., Kaib S., Reiman E.M. Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers. Neuroimage 2011, 54:1896-1902.
82. Liang W.S., Reiman E.M., Valla J., Dunckley T., Beach T.G., Grover A., Niedzielko T.L., Schneider L.E., Mastroeni D., Caselli R., Kukull W., Morris J.C., Hulette C.M., Schmechel D., Rogers J., Stephan D.A. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4441-4446.
83. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
84. MacAskill A.F., Kittler J.T. Control of mitochondrial transport and localization in neurons. Trends Cell. Biol. 2010, 20:102-112.
85. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
86. Mahley R.W., Hui D.Y., Innerarity T.L., Beisiegel U. Chylomicron remnant metabolism. role of hepatic lipoprotein receptors in mediating uptake. Arteriosclerosis 1989, 9:114-118.
87. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
88. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5644-5651.
89. Mauch D.H., Nägler K., Schumacher S., Göritz C., Müller E., Otto A., Pfrieger F. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294:1354-1357.
90. Minoshima S., Foster N.L., Kuhl D.E. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994, 344:895.
91. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 1996, 14:55-61.
92. Morrow J.A., Hatters D.M., Lu B., Hochtl P., Oberg K.A., Rupp B., Weisgraber K.H. Apolipoprotein E4 forms a molten globule. a potential basis for its association with disease. J. Biol. Chem. 2002, 277:50380-50385.
93. Nakamura T., Watanabe A., Fujino T., Hosono T., Michikawa M. Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol. Neurodegener. 2009, 4:35.
94. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994, 264:850-852.
95. Nathan B.P., Chang K.C., Bellosta S., Brisch E., Ge N., Mahley R.W., Pitas R.E. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol.Chem. 1995, 270:19791-19799.
96. Nathan B.P., Jiang Y., Wong G.K., Shen F., Brewer G.J., Struble R.G. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res. 2002, 928:96-105.
97. Nehlig A., Coles J.A. Cellular pathways of energy metabolism in the brain: is glucose used by neurons or astrocytes?. Glia 2007, 55:1238-1250.
98. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E., Jones P., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
99. Pellerin L., Bouzier-Sore A.-K., Aubert A., Serres S., Merle M., Costalat R., Magistretti P.J. Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 2007, 55:1251-1262.
100. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 1987, 917:148-161.
101. Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J. Biol. Chem. 1987, 262:14352-14360.
102. Pomara N., Bruno D., Nierenberg J.J., Sidtis J.J., Martiniuk F.T., Mehta P.D., Zetterberg H., Blennow K. TOMM40 poly-T variants and cerebrospinal fluid amyloid beta levels in the elderly. Neurochem. Res. 2011, 36:1124-1128.
103. Qiu Z., Hyman B.T., Rebeck G.W. Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J. Biol. Chem. 2004, 279:34948-34956.
104. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
105. Raichle M.E., MacLeod A., Snyder A.Z., Powers W.J., Gusnard D.A., Shulman G.L. A default mode of brain function. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:676-682.
106. Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 2008, 14:45-53.
107. Reger M.A., Watson G.S., Frey W.H., Baker L.D., Cholerton B., Keeling M.L., Belongia D.A., Fishel M.A., Plymate S.R., Schellenberg G.D., Cherrier M.M., Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 2006, 27:451-458.
108. Reger M.A., Watson G.S., Green P.S., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Cherrier M.M., Schellenberg G.D., Frey W.H., Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimer's Dis. 2008, 13:323-331.
109. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
110. Reiman E.M. Linking brain imaging and genomics in the study of Alzheimer's disease and aging. Ann. N. Y. Acad. Sci. 2007, 1097:94-113.
111. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3334-3339.
112. Reiman E.M., Caselli R.J., Yun L., Chen K., Bandy D., Minoshima S., Thibodeau S., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334:752-758.
113. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:284-289.
114. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8299-8302.
115. Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., Craig D.W., Coon K.D., Liang W.S., Herbert R.H., Beach T., Rohrer K.C., Zhao A.S., Leung D., Bryden L., Marlowe L., Kaleem M., Mastroeni D., Grover A., Heward C.B., Ravid R., Rogers J., Hutton M.L., Melquist S., Petersen R.C., Alexander G.E., Caselli R.J., Kukull W., Papassotiropoulos A., Stephan D.A. GAB2 alleles modify Alzheimer's risk in APOE ε4 carriers. Neuron 2007, 54:713-720.
116. Richter-Schmidinger T., Alexopoulos P., Horn M., Maus S., Reichel M., Rhein C., Lewczuk P., Sidiropoulos C., Kneib T., Perneczky R., Doerfler A., Kornhuber J. Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J. Neural Transm. 2011, 118:249-257.
117. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D., Rosiglitazone in Alzheimer's Disease Study Group Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6:246-254.
118. Roses A.D., Lutz M.W., Amrine-Madsen H., Saunders A.M., Crenshaw D.G., Sundseth S.S., Huentelman M.J., Welsh-Bohmer K.A., Reiman E.M. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2010, 10:375-384.
119. Salmon E., Kerrouche N., Perani D., Lekeu F., Holthoff V., Beuthienbaumann B., Sorbi S., Lemaire C., Collette F., Herholz K. On the multivariate nature of brain metabolic impairment in Alzheimer's disease. Neurobiol. Aging 2009, 30:186-197.
120. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070. Bapineuzumab 201 Clinical Trial Investigators.
121. Sato T., Hanyu H., Hirao K., Kanetaka H., Sakurai H., Iwamoto T. Efficacy of peroxisome proliferator-activated receptor-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 2011, 32:1626-1633.
122. Scarmeas N., Habeck C.G., Hilton J., Anderson K.E., Flynn J., Park A., Stern Y. APOE related alterations in cerebral activation even at college age. J. Neurol. Neurosurg. Psychiatry. 2005, 76:1440-1444.
123. Scarmeas N., Habeck C.G., Stern Y., Anderson K. APOE genotype and cerebral blood flow in healthy young individuals. JAMA 2003, 290:1581-1582.
124. Shaw P., Lerch J.P., Pruessner J.C., Taylor K.N., Rose A.B., Greenstein D., Clasen L., Evans A., Rapoport J.L., Giedd J.N. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007, 6:494-500.
125. Smith M.A., Drew K.L., Nunomura A., Takeda A., Hirai K., Zhu X., Atwood C.S., Raina A.K., Rottkamp C.A., Sayre L.M., Friedland R.P., Perry G. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?. Neurochem. Int. 2002, 40:527-531.
126. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
127. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
128. Stranahan A.M., Mattson M.P. Metabolic reserve as a determinant of cognitive aging. J. Alzheimers Dis. 2012, 30:S5-S13.
129. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.M., Jakes R., Huang D.Y., Pericak-Vance M.A., Schmechel D., Roses A.D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 91:11183-11186.
130. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M.A., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1977-1981.
131. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20:S265-S279.
132. Tanaka M., Vedhachalam C., Sakamoto T., Dhanasekaran P., Phillips M.C., Lund-Katz S., Saito H. Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4. Biochemistry 2006, 45:4240-4247.
133. Tesseur I., Van Dorpe J., Bruynseels K., Bronfman F., Sciot R., Van Lommel A., Van Leuven F. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol. 2000, 157:1495-1510.
134. Trachtenberg A.J., Filippini N., Cheeseman J., Duff E.P., Neville M.J., Ebmeier K.P., Karpe F., Mackay C.E. The effects of APOE on brain activity do not simply reflect the risk of Alzheimer's disease. Neurobiol. Aging 2012, 33:618.e1-618.e13.
135. Trachtenberg A.J., Filippini N., Ebmeier K.P., Smith S.M., Karpe F., Mackay C.E. The effects of APOE on the functional architecture of the resting brain. Neuroimage 2012, 59:565-572.
136. Trachtenberg A.J., Filippini N., Mackay C.E. The effects of APOE-ε4 on the BOLD response. Neurobiol. Aging 2012, 33:323-334.
137. Vaishnavi S.N., Vlassenko A.G., Rundle M.M., Snyder A.Z., Mintun M.A., Raichle M.E. Regional aerobic glycolysis in the human brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17757-17762.
138. Valla J., Berndt J.D., Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci. 2001, 21:4923-4930.
139. Valla J., Schneider L.E., Niedzielko T.L., Coon K.D., Caselli R.J., Sabbagh M.N., Ahern G.L., Baxter L., Alexander G., Walker D.G., Reiman E.M. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006, 6:323-330.
140. Valla J., Schneider L., Small A., Gonzalez-Lima F. Quantitative cytochrome oxidase histochemistry: applications in human Alzheimer's disease and animal models. J. Histotechnol. 2007, 30:235-247.
141. Valla J., Yaari R., Wolf A.B., Kusne Y., Beach T.G., Roher A.E., Corneveaux J.J., Huentelman M.J., Caselli R.J., Reiman E.M. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 2010, 22:307-313.
142. Verghese P.B., Castellano J.M., Holtzman D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011, 10:241-252.
143. Villain N., Desgranges B., Viader F., de la Sayette V., Mézenge F., Landeau B., Baron J.-C., Eustache F., Chételat G. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J. Neurosci. 2008, 28:6174-6181.
144. Vlassenko A.G., Vaishnavi S.N., Couture L., Sacco D., Shannon B.J., Mach R.H., Morris J.C., Raichle M.E., Mintun M.A. Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17763-17767.
145. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry. 2005, 13:950-958.
146. Weisgraber K.H., Rall S.C., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 1981, 256:9077-9083.
147. Wetterau J.R., Aggerbeck L.P., Rall S.C., Weisgraber K.H. Human apolipoprotein E3 in aqueous solution. I. evidence for two structural domains. J. Biol. Chem. 1988, 263:6240-6248.
148. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991, 252:1817-1822.
149. Wong-Riley M. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 1989, 12:94-101.
150. Xu P.T., Gilbert J.R., Qiu H.L., Ervin J., Rothrock-Christian T.R., Hulette C., Schmechel D.E. Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol. 1999, 154:601-611.
151. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R.W., Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 2006, 26:4985-4994.
152. Xu Q., Brecht W.J., Weisgraber K.H., Mahley R.W., Huang Y. Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer. J. Biol. Chem. 2004, 279:25511-25516.
153. Xu Q., Walker D., Bernardo A., Brodbeck J., Balestra M.E., Huang Y. Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J. Neurosci. 2008, 28:1452-1459.
154. Yang C.-P., Gilley J.A., Zhang G., Kernie S.G. ApoE is required for maintenance of the dentate gyrus neural progenitor pool. Development 2011, 4362:4351-4362.
155. Yao J., Rettberg J.R., Klosinski L.P., Cadenas E., Brinton R.D. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol. Aspects Med. 2011, 32:247-257.
156. Zhong N., Ramaswamy G., Weisgraber K.H. Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function. J. Biol. Chem. 2009, 284:27273-27280.
157. Zhong N., Weisgraber K.H. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J. Biol. Chem. 2009, 284:6027-6031.